Complementary edge

Abeona's gene therapies could have dosing, efficacy advantage for MPS III

The neurological manifestations of many lysosomal storage disorders are poorly treated because it hasn't been possible to get enough of an enzyme or gene therapy vector across the blood-brain barrier to replace dysfunctional proteins. Abeona Therapeutics LLC aims to improve on more advanced candidates for mucopolysaccharidosis III with preclinical gene therapies that can be delivered systemically to treat both CNS and peripheral manifestations of the disease.

No therapies are approved to treat mucopolysaccharidosis (MPS) III, a rare lysosomal storage disorder also known as

Read the full 833 word article

How to gain access

Continue reading with a
two-week free trial.